Juliana Mulligan And Ibogaine Patient Safety

Who is Juliana Mulligan in this conversation?

Juliana Mulligan established InnerSpace Ibogaine to provide independent consultation, preparation, and integration services rather than acting as a treatment facility. That distinction matters. A patient advocate can help people ask better questions, while an ibogaine provider must be able to answer them with records, credentials, procedures, and an emergency protocol.

Her experience is discussed in a Modern Psychedelics conversation with Juliana Mulligan and in an account of how ibogaine launched her recovery from addiction. The point is not to turn one person’s story into a universal clinical claim. It is to recognize how a near-catastrophe can sharpen attention to safety protocols, provider accountability, and patient welfare.

Juliana Mulligan has argued for public provider transparency and rigorous medical pre-screening to reduce preventable deaths in the ibogaine space. Her professional profile and her listing with Psychedelic Support’s practitioner network offer context for the harm reduction work people may encounter while researching preparation and integration.

“Safety is not a promise made by a provider. It is a set of conditions that can be inspected before treatment begins.”

On clinic vetting and patient education

That standard is especially relevant where underground clinics operate beyond consistent regulation. A flood dose, microdosing, or a discussion of noribogaine does not eliminate the need for medical supervision. The dose model may change, but the obligations of screening, risk mitigation, and informed consent remain.

The critical importance of ibogaine safety protocols

QT prolongation matters because it can create conditions for severe ventricular arrhythmia, including torsades de pointes. In the most serious circumstances, an arrhythmia can progress to cardiac arrest. This is why a clinic’s safety protocols must address more than a single pre-treatment ECG. Cardiac screening needs to be paired with a medication review, medical clearance, an electrolyte panel, and a plan for continuous monitoring.

Potassium and magnesium are not minor laboratory details. Hypokalemia and hypomagnesemia can materially increase vulnerability to QT prolongation and torsades de pointes. An electrolyte panel should inform whether potassium or magnesium must be corrected before any ibogaine administration. A metabolic panel can also help identify broader concerns that need medical review.

People sometimes hear “electrocardiogram” as if it were a one-time administrative checkpoint. In a responsible protocol, the ECG is part of a larger cardiac screening process. Depending on history and clinical judgment, that process may include repeated ECG findings, a holter monitor, review of heart rhythm history, and a decision not to proceed when contraindications cannot be responsibly managed.

Continuous monitoring and emergency preparedness

Safe ibogaine administration requires constant physical access to medical personnel trained in ACLS. Continuous monitoring from initial dose administration through the primary hallucinogenic and cardiovascular peak—often described as 24 to 36 hours—is a core risk mitigation measure. A defibrillator, oxygen, emergency cardiac medication, and a rehearsed emergency protocol are practical requirements, not decorative signals of seriousness.

The language of intensive care should not be borrowed casually, but a provider should be ready to explain what happens if a patient deteriorates. Is a registered nurse or other certified medical staff physically present? What emergency medicine training is available? Is there an emergency transfer agreement? Who uses the defibrillator? These are clinic vetting questions with direct implications for patient welfare.

Medical contraindications and drug interactions

Ibogaine cannot be evaluated apart from a person’s medications, substance use, psychiatric history, and organ function. SSRIs, MAOIs, stimulants, and other psychiatric drugs can create dangerous drug interactions, including serotonin toxicity or severe hypertension. A medication list is therefore not merely intake paperwork; it is an essential part of medical clearance and patient education.

For people with opioid use disorder, withdrawal management can be especially complicated. Methadone and buprenorphine have long elimination patterns and require a medically supervised stabilization or transition plan well in advance of ibogaine therapy. Abrupt changes in medication are not a do-it-yourself detox strategy. They are decisions that need clinical oversight, clear safety guidelines, and attention to overdose vulnerability.

Pre-existing liver impairment may slow hepatic conversion of ibogaine to noribogaine, changing clearance and prolonging cardiac vulnerability. Liver function testing, a metabolic panel, and toxicology review are therefore relevant to risk mitigation. So are hydration, nutrition, and a frank discussion of recent substance exposure. A good protocol leaves room to postpone treatment when the data do not support proceeding.

Psychological evaluation matters too. A psychiatric history of psychosis, mania, or severe dissociative conditions can change the risk profile for psychedelic therapy. Pre-screening should include psychological evaluation and informed consent that explain possible destabilization, not just anticipated recovery. The OPEN Foundation discussion of the ibogaine and iboga landscape is one example of how the subject is being framed beyond simplified benefit claims.

For a concise account of potential uses and dangers, readers may also encounter an explanation of what ibogaine is. Such material is most useful when it leads back to concrete questions about contraindications, medical supervision, and the adequacy of the proposed treatment setting.

How to vet an ibogaine clinic and provider

Clinic vetting is not an act of mistrust. It is an act of harm reduction. An ibogaine provider should be able to describe medical credentials, staffing ratios, pre-screening requirements, ECG policies, electrolyte testing, dosing procedures, continuous monitoring, and escalation decisions in specific terms. Evasion, pressure, or vague reassurance should be treated as information.

Juliana Mulligan emphasizes requesting detailed verification of medical credentials, emergency transfer agreements, and resuscitation protocols before booking. That advice makes provider accountability observable. It asks whether an operation can demonstrate patient safety rather than merely assert it. Independent accounts about finding an ibogaine clinic can help structure the first round of questions, but they do not replace individualized medical judgment.

• Who reviews the ECG, electrocardiogram, electrolyte panel, liver function, toxicology, and medication list before treatment?
• What contraindications lead the provider to decline, defer, or refer a patient elsewhere?
• How is QT prolongation monitored, and what exact emergency protocol applies if heart rhythm changes?
• Are ACLS-trained medical personnel on site with oxygen, a functioning defibrillator, emergency medication, and a defined transfer pathway?
• What aftercare, integration, peer support, and relapse-prevention planning are available after the acute session?

Reporting has made the stakes visible. A Rolling Stone examination of ibogaine’s benefits, dangers, and deaths and a critical discussion of “miracle drug” narratives each reinforce a basic point: public enthusiasm does not resolve unresolved safety questions.

People looking for structured information can review the site’s independent research guidance and practical topic coverage alongside their own clinician’s advice. Patient education works best when it makes uncertainty visible and encourages questions that protect patient welfare.

The role of psychological preparation and aftercare

Preparation is part of patient safety. Psychological evaluation, a discussion of psychiatric history, clear informed consent, and a realistic account of the treatment experience can reduce avoidable confusion. Harm reduction means understanding that a difficult experience is not evidence of therapeutic value, and that psychedelic medicine should not be presented as a shortcut around clinical judgment.

Aftercare and integration are equally important. A person leaving ibogaine treatment may have lower opioid tolerance, which can increase overdose danger if relapse occurs. Recovery planning should address housing, relationships, follow-up care, peer support, mental health needs, and a response plan for return to use. Structured integration is not a luxury attachment to treatment; it is a safety guideline for the period when people may be especially vulnerable.

Juliana Mulligan’s harm reduction perspective keeps attention on that longer arc. Addiction treatment cannot be measured only by the hours of a flood dose or by withdrawal management. It also includes whether a person has practical support for recovery, whether the provider communicates limits honestly, and whether aftercare remains available when the initial intensity has passed.

A piece on ibogaine’s potential relevance for chronically ill palliative patients illustrates why patient selection and medical context matter. A broad label such as opioid use disorder does not capture the complexity of comorbid illness, concurrent medication, or the distinct needs of a particular patient.

Advocating for industry accountability and regulation

Provider accountability is the bridge between individual clinic vetting and broader patient safety. It includes clear safety protocols, incident reporting, transparent qualifications, accurate dose information, ethical boundaries, and a willingness to refer out. It also includes recognizing the limitations of the evidence: no one should convert incomplete research into a blanket assurance that ibogaine is safe.

Juliana Mulligan has been direct about accountability in public discussions. Her contribution to “How Not to Do Ibogaine 101” centers patient safety in a landscape where underground clinics may not be subject to uniform standards. Likewise, an examination of ibogaine abuses and accountability points to the ethical stakes of transparent grievance and safety processes.

Ethics is operational. It appears in the way a provider handles contraindications, manages drug interactions, documents informed consent, responds to adverse events, protects a patient’s dignity, and refuses a treatment when the risk cannot be adequately mitigated. An independent patient advocate can help surface those questions; the responsibility to meet them rests with the provider.

Claims made around high-profile stories also deserve perspective. The discussion of Conor McGregor’s ibogaine advocacy may increase public interest, but celebrity attention is not medical clearance, cardiac screening, or evidence of a safe protocol.